سعر سبيراليبسي 500مجم 30 قرص ذائب بالفم 2023

Sprialypsy levetiracetam 500 mg orally disintegrating tablets, box of 30, Mash Premiere / SAS Pharma; antiepileptic.

• Partial-onset seizuresPopulation: 4 years and older, over 20 kg (US product)DailyMed (U.S. National Library of Medicine)
• Adjunctive therapy of myoclonic seizures in juvenile myoclonic epilepsyPopulation: 12 years and olderDailyMed (U.S. National Library of Medicine)
• Adjunctive therapy of primary generalised tonic-clonic seizures in idiopathic generalised epilepsyPopulation: 6 years and olderDailyMed (U.S. National Library of Medicine)

• Most common (>=5% more than placebo): adults - somnolence, asthenia, infection, dizziness; children - fatigue, aggression, nasal congestion, decreased appetite, irritability.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to levetiracetam (anaphylaxis and angioedema have occurred).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Behavioural abnormalities and psychotic symptoms (irritability, aggression); suicidal behaviour and ideation; somnolence and fatigue; anaphylaxis/angioedema; serious dermatological reactions (SJS/TEN); DRESS; coordination difficulties; withdrawal seizures.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Prolonged experience over two decades has not identified a drug-associated risk of major birth defects or miscarriage; animal studies showed developmental toxicity at doses similar to human doses; plasma levels may fall during pregnancy.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Excreted in human milk; no data on effects on the breastfed infant or milk production; weigh benefits of breastfeeding against maternal need.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Levetiracetam: Precise mechanism unknown; binds synaptic vesicle protein SV2A.